| Project/Area Number |
17K09938
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Jichi Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 分子標的療法 / LSD1阻害剤 / 急性Tリンパ性白血病 / 中枢神経白血病 / エピジェネティクス / 急性リンパ性白血病 / 癌 / 血液腫瘍学 / T-ALL |
|---|
| Outline of Final Research Achievements |
Treatment outcome of T-cell acute lymphoblastic leukemia (T-ALL) is still worse than that of other hematologic malignancies.Despite the fundamental role of lysine-specific demethylase 1 (LSD1) in T-cell leukemogenesis, conventional LSD1 inhibitors, such as tranylcypromine (TCP), were shown to be ineffective for T-ALL cells in several preclinical studies. We therefore modified TCP to develop novel LSD1 inhibitors with higher activity and specificity for T-ALL. One of the newly developed inhibitors, S2157, showed robust cytotoxicity against TCP-resistant T-ALL cells both in vitro and in xenotransplanted mice. Notably, S2157 could eradicate CNS leukemia because of its ability to efficiently pass through the blood-brain barrier. This brain-permeable LSD1 inhibitor is promising as a novel therapeutic agent for T-ALL with CNS involvement.
|
| Academic Significance and Societal Importance of the Research Achievements |
新規LSD1阻害剤S2157は、T-ALLに対して臨床応用可能なレベルの力価を有し、今まで治療が困難とされてきたCNS病変に対しても有効である可能性が示された。現在、T-ALLに対する分子標的薬として臨床応用されているものはなく、LSD1阻害剤はその第１号として既存の治療戦略への組み込みが期待される。
|
